Minimal important difference

Healthcare Management Administrators and Omada Health Partner to Control Rising Musculoskeletal Costs

Retrieved on: 
Tuesday, May 16, 2023
Partnership, Therapy, HMA, DSM-IV codes, Pain, MSK, Human musculoskeletal system, Human, DPT, Minimal important difference, Nursing

BELLEVUE, Wash., May 16, 2023 /PRNewswire/ -- Healthcare Management Administrators (HMA), a pioneer in self-funded health benefit programs and one of the nation's largest third-party administrators, today announced that it is partnering with Omada Health to offer virtual-first physical therapy and musculoskeletal (MSK) care.

Key Points: 
  • BELLEVUE, Wash., May 16, 2023 /PRNewswire/ -- Healthcare Management Administrators (HMA), a pioneer in self-funded health benefit programs and one of the nation's largest third-party administrators, today announced that it is partnering with Omada Health to offer virtual-first physical therapy and musculoskeletal (MSK) care.
  • Musculoskeletal system disorders consistently drive high costs to plans and are acknowledged across the healthcare industry as a top concern for employers.
  • "With Omada, members don't have to choose between clinical quality and convenience," said Todd Norwood PT, DPT, Senior Director of Clinical Services at Omada.
  • HMA's new MSK Program through Omada Health will go live in January 2024.

DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease

Retrieved on: 
Monday, January 23, 2023
Visual analogue scale, MD, Safety, University, NSAID, University of Tennessee Health Science Center, Ibuprofen, Low back pain, AACN Advanced Critical Care, Minimal important difference, Neurosurgery, Conference, North American Spine Society, Pain, Spine, VAS, IDCT, Cell, Aspirin, Trial of the century, FDA, Annual general meeting, MCID, American Academy, Synthetic control method, MRI, Philippine Orthopedic Center, NASS, Disability, ODI, Quality of life, Patient, SALT, DDD, Medical imaging, Birth control, Nursing, Pharmaceutical industry, Tissue, Intervertebral disc

SALT LAKE CITY, Jan. 23, 2023 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced positive two-year clinical data from its first-in-human clinical study of IDCT (rebonuputemcel), an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease (DDD).

Key Points: 
  • SALT LAKE CITY, Jan. 23, 2023 /PRNewswire/ -- DiscGenics, Inc. , a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced positive two-year clinical data from its first-in-human clinical study of IDCT (rebonuputemcel), an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease (DDD).
  • In the low dose IDCT group (3,000,000 cell/mL; n=20), there was a trend in improvement of clinical outcomes, though inconsistent.
  • The 60-subject study was designed to evaluate the safety and preliminary efficacy of IDCT for the treatment of symptomatic lumbar degenerative disc disease versus vehicle and saline controls.
  • DiscGenics has submitted a full clinical study report to the U.S. Food & Drug Administration's (FDA) Office of Tissues and Advanced Therapies (OTAT).

Biophytis: Biophytis presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022

Retrieved on: 
Tuesday, April 19, 2022
Euronext Growth, SAE, EMA, Ageing, Board, Population, COVID-19, Duchenne muscular dystrophy, Security (finance), Phase, U.S. Securities and Exchange Commission, CET, MD, FAS, Minimal important difference, Therapy, Doctor of Philosophy, Program, Patient, FPI, DMD, MCID, Conference, Review, ISIN, Company, SARA, Ticker, SEC, Forward-looking statement, American depositary receipt, Physician, FDA, Asilomar International Conference on Climate Intervention Technologies, Risk factors for breast cancer, PP, ADS, AMF, Pharmaceutical industry, Medical device, Sarcopenia, Frailty, Nasdaq

ICFSR is the key international scientific event on Frailty and Sarcopenia and is attended by leading researchers, physicians and Biotech/Pharma in this field.

Key Points: 
  • ICFSR is the key international scientific event on Frailty and Sarcopenia and is attended by leading researchers, physicians and Biotech/Pharma in this field.
  • Jean Mariani, MD, PhD (Board Director) will give an oral presentation on the results of the Phase 2 SARA-INT trial for the treatment of Sarcopenia.
  • The Minimal Clinically Important Difference (MCID) for the 400MWT in sarcopenia is 0.1 m/s.
  • The objective is to have a FPI (First patient In) for this new study at the end of H2 2022.